journal may also suspect misconduct, while others may raise suspicions of misconduct after publication of a study. Scientific misconduct ranges from Salami publishing, data duplication, (self-) plagiarism, forging, trimming, to data falsification, and fabrication ( Figure 4 ). Since 2012, upon request by the editors of the European Heart Journal (EHJ) and Cardiovascular Research (CVR) various types of misconduct have been investigated by the committee, including improper animal experiments, unethical studies of patients or human tissues, manipulation of tracings, images, or other study data and plagiarism.
Animal experiments
Proper handling of animals during any kind of experimentation has become highly regulated by law in most countries and by the European and American Guidelines for the Care and Use of Laboratory Animals.
3,4 Such laws and recommendations are commonly implemented by the respective animal research committees of universities and other research institutes, albeit there may be important differences in the stringency of their implementation in different institutions and different countries. It has, therefore, become an important task for reviewers and editors alike to assure proper animal handling in research reported in submitted manuscripts. Cardiovascular Research receives the majority of the experimental studies involving animal research and has a dedicated Assistant Editor for ethical review of all studies. However, basic research papers including animal studies also constitute about 20% of the submissions to the European Heart Journal. Furthermore, some animal studies are now also submitted to the specialty journals (Figure 1) . Particular care has therefore to be taken by editors-in-chief that anaesthesia or euthanasia, animal care, and sample sizing are properly performed according to EU regulations and ethical standards and that ethical approval has been obtained. If not, such cases may be forwarded to the Ethics Committee for further review and recommendations. After investigation, if the findings show that the appropriate regulations have not been adhered to, the Committee generally recommends that the manuscripts should be rejected.
Studies of patients or human tissues
Although in the past human tissue could be obtained easily, the use of such material for scientific purposes is now highly regulated with again quite important differences amongst different countries. Often, tissues obtained at surgery or, from donated human hearts, but considered unsuitable for transplantation are used in experimental protocols. In some countries, organ donation for transplantation includes permission for transplantation-related research, but not for other types of research. Thus, these cultural and political differences have to be considered by the Ethics Committee as they are handling cases from many countries around the world. Importantly, if a particular study is questioned the ethics committee investigates whether the local regulations have been followed, ethical approval has been obtained, and patients or their family have been informed about the use of human tissues. 
Plagiarism
Although plagiarism has been a common phenomenon for centuries, the present globalization of information has made it worse. Indeed, identical papers in different languages, particularly those not easily read by Westerners such as those written in Chinese or Japanese among others are hard to detect. However, from an ethical point of view, it is clear that identical papers in two different languages are inappropriate. An exception is made for review articles that are clearly referencing the original paper. Duplication of papers is largely picked up with modern tools for plagiarism detection such as iThenticate that is part of the manuscript handling tools of several ESC journals. Nevertheless, sometimes a duplication of results is missed through partial rewriting and the Ethics Committee has had to handle a number of such cases.
Clinical trials
For many years, the www.ClinicalTrials.gov platform has provided an opportunity to register trials and their design. The platform was initiated to assure that trials define their design, their inclusion and exclusion criteria, and, most importantly, their endpoints beforehand, in order to avoid post hoc changes that may introduce bias. The Ethics Committee was faced with the question, should clinical trials be published that are neither registered in www.clinicaltrials.gov nor in any other registry of a University or research institution. In such instances, the Ethics Committee recommended that such manuscripts should be rejected.
The question has been raised whether monitoring and data management procedures of clinical trials have been handled correctly. In such cases, which require extensive investigation of the study procedures, the Ethics Committee recommends sending upcoming allegations to the drug registration agencies, i.e. the European Medicines Agency (EMA) and/or the Federal Drug Administration (FDA).
Discussion and conclusions
In 5 years, the ESC Journals Family Ethics Committee has investigated 20 cases. Fortunately, the number of cases per year was very low, considering that over 3000 manuscripts are being submitted annually to the European Heart Journal and about 1400 to Cardiovascular Research. The other ESC journals, covering different areas of cardiovascular disease and science, have so far not sought assistance from the Ethics Committee either, because the editors could resolve all issues within their editorial boards, or because they were not sufficiently aware of the services offered by the Committee. Of note, in addition to the cases investigated by the ESC Journals Family Ethics Committee, the editors of the European Heart Journal and Cardiovascular Research rejected a number of manuscripts because of apparent duplicate publications, or other ethical issues. Only in a minority of the investigated cases did the ESC Journals Family Ethics Committee recommend that a manuscript be rejected, while in others, no specific action was necessary either, because the case was already handled elsewhere or because no misconduct could be substantiated.
Working mode
Generally, the committee and the editors follow the guidelines and flowcharts of the Committee on Publication Ethics.
2 If a possible ethical issue is related to the university of one of the committee members, he or she abstains from the discussion in the committee. Anonymous allegations without substantive data are generally dismissed. Expert advice is commonly obtained on specific issues such as stem cell biology, anaesthetics for animal studies, and invasive procedures. With this information at hand, the committee has been able to provide advice to the editors to resolve the respective issues. The final decision rests with the editors. Nevertheless, in all cases the editors followed the advice of the Ethics Committee. As of 2016, the Cardiovascular Research instructions to authors explicitly state that studies using certain procedures for anaesthesia/euthanasia in animal procedures will no longer be accepted and the instructions include clear rules for figures and image processing (see www: https://academic.oup.com/cardiovascres/ pages/General_Instructions). It appeared difficult, if not impossible, to properly investigate allegations of misconduct in laboratory studies. If the allegations were severe, the head of the department, the integrity officer of the university, if such officer can be identified, or the Dean of the University was contacted.
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In summary, during the initial period of almost 5 years the ESC Journals Ethics Committee investigated 20 cases of possible scientific misconduct at the request of the editors of the European Heart Journal and Cardiovascular Research. During that period, over 20 000 manuscripts were submitted to these two journals, and only a minute percentage were questioned for their scientific integrity.
The Committee has greatly facilitated the difficult decisions made by the editors of the European Heart Journal and Cardiovascular Research and should continue to review ethical issues when these arise. 
